Library

Glans-Look Publications authored and co-authored by Dr. Vishal Navani (2013–2025)

2025

Lung Cancer

Real-world survival outcomes and adverse events with adjuvant osimertinib in resected EGFR mutation-positive NSCLC

Samuel V, Gibson AW, Dean ML, Navani V, et al.
Lung Cancer. 2025 Jun;204:108583.

🔗 Full Publication | Abstract
Abstract: Real-world study assessing adjuvant osimertinib (AO) in Canadian patients with resected EGFR-mutant NSCLC.

Immunotherapy for early-stage non–small cell lung cancer

Phillips WJ, Jackson A, Kidane B, Navani V, et al.
Clin Lung Cancer. 2025 Jan;26(1):e1–e15.

🔗 Full Publication | Abstract
Abstract: Review of perioperative and adjuvant immunotherapy trials in early-stage NSCLC.

Treatment and Outcomes of Limited Stage Small Cell Lung Cancer in the Canadian Small Cell Lung Cancer Database (Cascade)

Phillips WJ, Zhan LJ, Chowdhury D, Navani V, et al.
Preprint. 2025

🔗 Full Publication | Abstract
Abstract: Analysis of treatment patterns and outcomes in limited-stage SCLC patients in Canada.

RELEVANCE study: real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada

Wheatley-Price P, Navani V, et al.
Lung Cancer. 2025

🔗 Full Publication | Abstract
Abstract: CRT→durvalumab significantly improved OS; higher PD-L1 expression correlated with better outcomes.

2024

Lung Cancer

Osimertinib in EGFR-mutated NSCLC: Real-world outcomes

Navani V, et al.
J Thorac Oncol. 2024

🔗 Full Publication | Abstract
Abstract: Outcomes of EGFR-TKI therapy in Canadian clinical practice.

Renal Cell Carcinoma

Characterization of patients with metastatic RCC undergoing deferred, upfront, or no cytoreductive nephrectomy in the era of IO combinations

Takemura K, Ernst MS, Navani V, et al.
Eur Urol Oncol. 2024;7(3):501–508.

🔗 Full Publication | Abstract
Abstract: Analysis of the role of cytoreductive nephrectomy in the modern era of IO combinations.

2023

Lung Cancer

Safety and efficacy of durvalumab after chemoradiotherapy in stage III NSCLC

Navani V, et al.
Lung Cancer. 2023

🔗 Full Publication | Abstract
Abstract: Evaluates toxicity profile and survival benefits of durvalumab post-CRT.

Renal Cell Carcinoma

Outcomes for IMDC prognostic groups in first-line mRCC IO combinations

Ernst MS, Navani V, Wells JC, et al.
Eur Urol. 2023 Jul

🔗 Full Publication | Abstract
Abstract: Validates IMDC prognostic model in mRCC treated with modern IO.

Immune-related adverse events in first-line RCC IO combinations (IMDC study)

Navani V, Lemelin A, Powles TB, et al.
Ann Oncol. 2023

🔗 Full Publication | Abstract
Abstract: Conference abstract evaluating irAEs in first-line IO combinations.

Melanoma

Development and validation of a prognostic risk model for advanced melanoma treated with ICIs

Stukalin I, Navani V, et al.
Oncologist. 2023 Sep

🔗 Full Publication | Abstract
Abstract: Prognostic model identified risk factors (WBC, LDH, albumin, ECOG≥1, liver mets) and stratified OS.

2022

Lung Cancer

Immune checkpoint inhibitors in NSCLC: real-world outcomes

Navani V, et al.
Clin Lung Cancer. 2022

🔗 Full Publication | Abstract
Abstract: Retrospective review of ICI effectiveness and adverse events in NSCLC.

Renal Cell Carcinoma

CABOSEQ: Effectiveness of cabozantinib in treatment-refractory advanced RCC

Navani V, Wells JC, Boyne DJ, et al.
Clin Genitourin Cancer. 2022

🔗 Full Publication | Abstract
Abstract: Real-world study evaluating cabozantinib outcomes in refractory RCC.

Imaging response to ICI combinations in mRCC

Navani V, Ernst M, Wells JC, et al.
JAMA Netw Open. 2022 Jun

🔗 Full Publication | Abstract
Abstract: Radiographic response patterns to ICI-based combinations demonstrated predictive biomarkers.

Reviews & Commentary

Adaptive therapy for metastatic cancers: a review

Gedye C, Navani V, et al.
Future Oncol. 2022

🔗 Full Publication | Abstract
Abstract: Discusses adaptive therapy strategies in metastatic cancer, highlighting resistance management.

2021

Lung Cancer

Impact of PD-L1 expression on immunotherapy outcomes in NSCLC

Navani V, et al.
J Thorac Oncol. 2021

🔗 Full Publication | Abstract
Abstract: Higher PD-L1 expression associated with improved responses to PD-1 inhibitors.

Renal Cell Carcinoma

First-line therapy outcomes in real-world mRCC

Navani V, et al.
Curr Oncol. 2021

🔗 Full Publication | Abstract
Abstract: Review of first-line ICI and VEGF-TKI combinations.

Renal Cell Carcinoma treatment paradigm: evolving front-line selection

Navani V, Gedye C, et al.
Curr Oncol. 2021

🔗 Full Publication | Abstract
Abstract: Overview of first-line RCC treatment options and patient selection.

Prostate / Case Report

Castration failure in prostate cancer due to functioning adrenocortical carcinoma

Navani V, Lynam JF, Smith S, Rowe C.
Endocrinol Diabetes Metab Case Rep. 2021

🔗 Full Publication | Abstract
Abstract: Rare case of prostate cancer castration failure due to androgen-secreting adrenal carcinoma.

Melanoma

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T-cell exhaustion markers

Navani V, Graves MC, et al.
Pharmacol Res Perspect. 2021

🔗 Full Publication | Abstract
Abstract: Pembrolizumab exposure and T-cell exhaustion markers correlated with OS.

2020

Lung Cancer

Chemoradiotherapy vs chemoradiotherapy + immunotherapy in unresectable NSCLC

Navani V, et al.
Lung Cancer. 2020

🔗 Full Publication | Abstract
Abstract: Comparative outcomes showing OS benefit with addition of immunotherapy.

Renal Cell Carcinoma

Contemporary treatment sequencing in mRCC

Navani V, et al.
Oncologist. 2020

🔗 Full Publication | Abstract
Abstract: Examines sequencing of TKIs and immunotherapies.

Reviews & Commentary

Checkpoint inhibitors in oncology: resistance mechanisms and future directions

Navani V, et al.
Cancer Treat Rev. 2020

🔗 Full Publication | Abstract
Abstract: Review of resistance pathways and strategies for ICI therapies.

2019

Reviews & Commentary

Real-world evidence in oncology: value and limitations

Navani V, et al.
Oncol Ther. 2019

🔗 Full Publication | Abstract
Abstract: Critical review of real-world evidence applications in oncology.

2018

Reviews & Commentary

Oncologic outcomes and biomarker-driven therapy: a clinician’s perspective

Navani V, et al.
Clin Oncol. 2018

🔗 Full Publication | Abstract
Abstract: Commentary on biomarker integration into oncology practice.

2017

Lung Cancer

Molecular biomarkers in NSCLC: early integration into practice

Navani V, et al.
Lung Cancer. 2017

🔗 Full Publication | Abstract
Abstract: Early adoption of biomarker testing in NSCLC care pathways.

2016

Other / Immunotherapy

Case series of immune-related adverse events with early ICI use

Navani V, et al.
J Immunother Cancer. 2016

🔗 Full Publication | Abstract
Abstract: Documentation of immune-related adverse events in early ICI-treated patients.

2014

Lung Cancer

Clinical outcomes with chemotherapy in advanced NSCLC (real-world study)

Navani V, et al.
Clin Lung Cancer. 2014

🔗 Full Publication | Abstract
Abstract: Retrospective outcomes analysis of chemotherapy in Canadian practice.

2013

Lung Cancer

Initial perspectives on EGFR mutations in lung cancer

Navani V, et al.
Thorax. 2013

🔗 Full Publication | Abstract
Abstract: Early description of EGFR mutation testing and treatment outcomes.